Clearline Capital LP Acquires Shares of 83,681 uniQure N.V. $QURE

Clearline Capital LP acquired a new stake in uniQure N.V. (NASDAQ:QURE) during the fourth quarter, Holdings Channel.com reports. The fund acquired 83,681 shares of the biotechnology company’s stock, valued at approximately $2,002,000.

A number of other large investors have also recently made changes to their positions in QURE. State Street Corp lifted its stake in shares of uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. MPM Bioimpact LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $33,062,000. Finally, Fred Alger Management LLC purchased a new stake in shares of uniQure in the third quarter valued at about $75,320,000. 78.83% of the stock is owned by institutional investors.

Insider Buying and Selling at uniQure

In related news, insider Jeannette Potts sold 5,237 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the sale, the insider owned 133,246 shares in the company, valued at approximately $3,686,916.82. This trade represents a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David D. Meek sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director owned 39,747 shares of the company’s stock, valued at $1,075,553.82. This trade represents a 4.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 101,054 shares of company stock valued at $2,655,791 in the last three months. 4.65% of the stock is owned by corporate insiders.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure said it plans to submit a BLA for AMT-130 in Huntington’s disease after the FDA indicated the company’s three-year data may support accelerated approval, a major regulatory win that could speed the drug toward market. Article Title
• Positive Sentiment: Analysts turned more constructive after the FDA update, with Cantor Fitzgerald upgrading QURE to overweight and lifting its price target, reinforcing the market’s bullish reaction. Article Title
• Positive Sentiment: Options activity also picked up, with traders buying unusually large volumes of call options, suggesting strong speculative demand tied to the FDA catalyst. Article Title

uniQure Stock Performance

NASDAQ QURE opened at $48.16 on Thursday. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $21.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company has a market capitalization of $3.04 billion, a PE ratio of -13.84 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. On average, research analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Leerink Partners reiterated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and increased their target price for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a report on Tuesday, May 5th. Finally, TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.